Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection

  • STATUS
    Recruiting
  • End date
    Dec 31, 2023
  • participants needed
    575
  • sponsor
    National Taiwan University Hospital
Updated on 24 January 2021
HIV Infection
hepatitis
vaccination
hepatitis b antigen
HIV Vaccine
immune globulin
hepatitis b core antibody
engerix-b

Summary

The primary aim of this open-label, randomized control trial is to compare the immunogenicity at week 28 after 20g HBV vaccine (at week 0, 4, 24) versus 40g HBV vaccine (40-g at week 0, 4, 24 week) among HIV-positive patients or HIV-negative MSM who were born in Taiwan after July 1986 and tested negative for all HBV serological markers. The secondary aims are to assess the safety of double-dose HBV vaccination, the proportions of high-level responders (anti-HBs antibody >100 mIU/ml) at weeks 28 and 48, the serological responses at week 48, and incident HBV infection (indicated by appearance of anti-HBc and/or HBsAg) at week 48.

Description

I. Study procedures:

  1. Well explain, complete inform and consent documents
  2. A blood test for hepatitis B surface antigen (HBsAg), anti-hepatitis B surface antibody (anti-HBs antibody), anti-hepatitis B core antibody (anti-HBc antibody), anti-HCV and RPR will be performed first.
  3. The patients with all negative seromarkers (within 1 month) will be allocated to two groups (random blank=4), a standard-dose booster of 20g and a double-dose booster of 40g. For patients receiving 40g, two 20g of vaccines are injected at both sides of deltoid muscles. The schedules of booster vaccination are the same in two groups, which is at 0, 1, 6 months.
  4. To detect and manage possible immediate and severe allergic reaction, patients who received vaccination will be observed for 30 minutes after injection.
  5. The solicited adverse effect will be recorded on the diary card if occurred in 7 days after each dose of vaccination.
  6. The titer of hepatitis B surface antibody will be examined before booster vaccination, at the 4th week, the 24th week, 28th week, 48th week. By comparing the responses in the two groups, the effect of different doses of booster vaccination can be evaluated. For those HIV-negative individuals at baseline, HIV screening test will be evaluated every 6 months during the study, at the 24th week, the 48th.
  7. To screen the acquisition of hepatitis B, the anti-HBc antibody and HBsAg will be examined at the 48th week
  8. To screen the acquisition of hepatitis C and syphilis, anti-HCV and RPR will be examined at the 24th week, the 48th week
  9. The results of the study will be informed by phone or the physician during the follow-up care.
  10. The serum/blood samples will be preserved in the research lab of the department of internal medicine and kept for 20 years. During this period, the sample will be applied or used in other studies after the patients and the Research Ethics Committee both agreed.
  11. During the follow-up care, the treatment or record of hospitalization will be recorded or reviewed.
  12. The participants will drop out of clinical trial when protocol violation occurred or the participant is not willing to continue.

Details
Condition HIV infection, Immunodeficiency, Hepatitis B, Primary Immunodeficiency Disorders, HIV Infections, Immunization; Infection, Immunization; Infection, human immunodeficiency virus, hiv disease, Immunization; Infection
Treatment Engerix-B
Clinical Study IdentifierNCT03854630
SponsorNational Taiwan University Hospital
Last Modified on24 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Men who have sex with men (MSM)
Birth date after 1986/7/1 and aged 20 years or older
Seronegative for HBsAg, anti-HBs (<10 mIU/ml), and anti-HBc at screening (within 1 month of the first dose)
Regularly receiving HIV care for HIV-positive patients over the past 6 months
Seeking VCT for at least once for HIV-negative patients over the past 12 months

Exclusion Criteria

Active infection or malignancy within 12 months of screening
Receiving chemotherapy, immunosuppressant, or IVIG within 12 months of screening
Received higher than 5 mg of prednisolone, including IV, oral, or topical form, per day for more than 1 weeks within 6 months of screening
Receiving HBV vaccination within 1 months of screening, or being allergic to HBV vaccine
Receiving other vaccination within 1 months of screening, such as influenza, pneumococcus, HPV, HAV, varicella vaccine
Stage 4 and 5 of chronic kidney disease (GFR<30 mL/min/1.73m), or receiving dialysis
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note